Drugs in Dev. Ophthalmology
Phase II
Israel 
Lead Product(s) : Selenium Sulfide
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Azura Ophthalmics Expands Broad Intellectual Property Portfolio to 12 U.S. and European Patents
Details : AZR-MD-001 harnesses the power of selenium sulfide (SeS2) in an easy-to-use ophthalmic ointment preparation applied directly to the meibomian glands on the eye lid.
Product Name : AZR-MD-001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 19, 2022
Lead Product(s) : Selenium Sulfide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TRS01,Adapalene
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Company received important feedback on its trial design and program for its TRS01 Phase 3 program in uveitis, including feedback on its nonclinical and CMC plans supporting submission of a New Drug Application (NDA) in the U.S.
Product Name : TRS01
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 17, 2020
Lead Product(s) : TRS01,Adapalene
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CSF-1
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Bluestem Capital
Deal Size : $30.0 million
Deal Type : Series C Financing
Orasis Raises $30 Million to Advance the Clinical Development of Novel Treatment for Presbyopia
Details : Proceeds from the financing will be used to advance Orasis’ lead eye drop candidate for the treatment of presbyopia symptoms through completion of its Phase 3 clinical trials.
Product Name : PresbiDrops
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 09, 2020
Lead Product(s) : CSF-1
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Bluestem Capital
Deal Size : $30.0 million
Deal Type : Series C Financing
Reset All
